期刊文献+

NSCLC患者外周血淋巴细胞抗癌药敏试验与化疗疗效的相关性 被引量:11

Relationship between Sensitivity of Peripheral Blood Lymphocytes to Chemotherapy and Chemotherapeutic Effect in Patients with Non-Small Cell Lung Cancers
下载PDF
导出
摘要 目的研究非小细胞肺癌(NSCLC)患者外周血淋巴细胞(PBL)抗癌药敏试验与化疗疗效的相关性,为临床肿瘤个体化化疗提供依据。方法52例NSCLC患者PBL接受四甲基偶氮唑蓝(MTT)药敏试验,根据结果分为敏感组和不敏感组。敏感组根据药敏结果化疗,不敏感组采用常规方案化疗,观察各组临床近期疗效;其中29例初治患者化疗2周期后再次取PBL接受MTT药敏试验。结果52例患者PBL对7种化疗药物的体外敏感性顺序依次为:长春瑞宾、吉西他滨、泰索帝、紫杉醇、丝裂霉素、长春地辛和顺铂,与临床实践基本一致。敏感组和不敏感组近期临床有效率分别为73.68%(14/19)和6.45%(2/31),差异有显著性(P<0.01);29例初治患者PBL在化疗前后总敏感率分别为28.64%(110/348)和22.99%(80/348),差异有显著性(P<0.05)。结论PBL抗癌药敏试验有助于指导临床肿瘤个体化化疗和预测化疗疗效。化疗后PBL对化疗药物的敏感性有不同程度下降。 Objectives To explore the relationship between to chemotherapy and chemotherapeutic effects and to provide the the sensitivity of peripheral blood lymphocytes (PBL) data for individualized chemotherapy in patients with non-small cell lung cancer (NSCLC). Methods Fifty two patients with NSCLC were divided into sensitive group and re sistive group according to the degree of sensitivity of PBL to chemotherapy determined by MTT assay. The patients in the sensitive group were treated according to the result of MTT assay. The patients in the resistive group were treated by the routine chemotherapy. Short-term responses to the chemotherapy were evaluated in 50 patients, among whom, 29 patients who accepted the first chemotherapy received again MTT assay of PBL after 2 cycles of chemotherapy. Results Vi norelbine, gemcitabine, taxotere, paclitaxel, mitomycin, vindesine and cisplatin were arranged in the order of PBL sensi tivity to anti cancer drugs in these 52 cases, which was consistent with NSCLC sensitivity to these drugs observed by clinical practice. The short term response rates in the sensitive group and resistive group were 73.68% (14/19) and 6. 45% (2/31), respectively. There was significantly difference in the response rate between both the groups (P〈0.01). Chemosensitivity of PBL in 29 patients who accepted no chemotherapy previously was significantly higher (28. 64%, 110/348) before the chemotherapy than that (22.99% ,80/348) after the chemotherapy (P〈0. 05). Conclusion The sensitivity of PBL to anti cancer drugs is helpful to individualized chemotherapy and prediction of the curative effect in patients with NSCLC. The sensitivity of PBL to the drugs descends to different extent after the chemotherapy.
出处 《华南国防医学杂志》 CAS 2007年第4期19-21,共3页 Military Medical Journal of South China
关键词 MTT药敏试验 化疗 外周血淋巴细胞 非小细胞肺癌 MTF Chemosensitivity Assay Chemotherapy Peripheral Blood Lymphocytes Non-Small Cell Lung Cancer
  • 相关文献

参考文献13

  • 1[1]Singh B,Li R,Xu L,et al.Prediction of survinval in patients with head and neck cancer using the histoculture drug response assay[J].Head Neck,2002,24(5):437-442 被引量:1
  • 2[2]Sato S,Kobayashi Y,Okuma Y,et al.Establishment and characterization of a cell-line originated from human mucinous cystadenocarcinoma of the ovary[J].Hum Cell,2002,15(3):171-177 被引量:1
  • 3[3]Govindan R,Arquette MA.The Washington Manual of Oncology[M].天津:天津科技翻译出版公司,2004.240-241 被引量:1
  • 4[4]Dubey S,Schiller JH.Chemotherapy for advanced non-small cell lung cancer[J].Hematol Oncol Clin North Am,2004,18(1):101-114 被引量:1
  • 5高建飞,饶智国,王军,张新华,朱宇泽,欧武陵,章必成,杜光祖.异长春花碱联合顺铂治疗晚期NSCLC的研究[J].华南国防医学杂志,2005,19(2):7-9. 被引量:3
  • 6高建飞,杜光祖,章必成,张新华,王军,朱宇泽,欧武陵.HMVP与HVP方案治疗晚期非小细胞肺癌前瞻研究[J].华南国防医学杂志,2004,18(4):8-11. 被引量:4
  • 7[7]Kovac V,Smrdel U.Meta-analyses of clinical trials in patients with non-small cell lung cancer[J].Neoplasma,2004,51(5):334-340 被引量:1
  • 8韩宝惠.非小细胞肺癌治疗的循证医学新进展[J].上海医学,2005,28(6):451-455. 被引量:7
  • 9[9]Gollapud S,Gupta S.Anti-P-glycoprotein antibody-induced apoptosis of activated peripheral blood lymphocytes:a possible role of P-glycoprotein in lymphocyte survival[J].J Clin Immunol,2001,21(6):420-430 被引量:1
  • 10[10]Juszczynski P,Niewiarowski W,Krykowski E,et al.Expression of the multidrug resistance-associated protein (mrp) gene in chronic lymphocytic leukemia[J].Leuk Lymphoma,2002,43(1):153-158 被引量:1

二级参考文献34

  • 1尹德领.卵巢癌化疗药物耐药性机理的研究[J].国外医学(妇产科学分册),1994,21(5):293-294. 被引量:5
  • 2吕卫国,谢幸.铂类耐药和治疗后复发卵巢癌的再次化疗[J].国外医学(妇产科学分册),1994,21(5):290-292. 被引量:4
  • 3何琪杨.肿瘤细胞多药抗性基因的表达调控[J].国外医学(分子生物学分册),1995,17(6):277-280. 被引量:6
  • 4[1]Cortes J, Rodriguez J, Calvo E, et al . Paclitaxcl, cisplatin, and vinorelbine combination chemotherapy in metastatic non - smallcell lung eacer. Lin Oncol,2004,27(3):299~ 303 被引量:1
  • 5[2]Depierre A, Chastang C, Quoix E, et al . Vinorelbine versus vinorelbine plus cisplatin in advanced non - small lung cancer: a randomezed trial. Ann Oncol, 1994,5(1) :37 ~42 被引量:1
  • 6[3]Chen YM, Perng RP, Shih JF, et al . A randomisd phase Ⅱ study of weekly paclitaxel or vinorelbine in combination with cisplatin against inoperable non - small - cell lung cancer previously untreated. Br J Cancer,2004,90(2):359 ~ 365 被引量:1
  • 7[4]Laack E, Dickgreber N, Muller T, et al . Randomzed phase Ⅲstudy of gemcitabine and vinorelbine versus gecitabine, vinorelbine, and cisplatin in the treatment of advanced non - cell lung cancer:from the German and Swiss Lung Cancer Study Group. JClin Oncol,2004,22(12) :2348 ~ 2356 被引量:1
  • 8The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med, 2004, 350: 351-360. 被引量:1
  • 9Nakagawa M, Tanaka F, Tsubota N, et al. A randomized phase Ⅲ trial of adjuvant chemotherapy with UFT for completely resected pathological stage I non-small-cell lung cancer: the West Japan Study Group for Lung Cancer Surgery (WJSG)-the 4th study. Ann Oncol, 2005, 16: 75-80. 被引量:1
  • 10Hotta K, Matsuo K, Ueoka H, et al. Role of adjuvant chemotherapy in patients with resected non-small-cell lung cancer:reappraisal with a meta-analysis of randomized controlled trials. J Clin Oncol, 2004, 22: 3860-3867. 被引量:1

共引文献31

同被引文献95

引证文献11

二级引证文献39

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部